Condition: Premature · Sponsor: The University of Texas Health Science Center at San Antonio
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
This description comes directly from the study's public registry record.
Cynthia Blanco, MD, MSCI-TS · 210-567-5225 · blanco@uthscsa.edu
Diana Anzueto Guerra · 210-567-5254 · anzuetod@uthscsa.edu
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| University Health System | San Antonio, Texas, United States | Recruiting |
| University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05380401